IVBT (Innovation1 Biotech) Equity-to-Asset: -27.35 (As of Feb. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IVBT Innovation1 Biotech Inc IVBT
12 GF Score
Price $0.00
View Full Analysis

What is Innovation1 Biotech Equity-to-Asset?

Innovation1 Biotech IVBT 12 Equity-to-Asset is -27.35 as of Feb. 2024. GuruFocus rates IVBT with a GF Score™ of 12/100.

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Innovation1 Biotech's Total Stockholders Equity for the quarter that ended in Feb. 2024 was $-3.34 Mil. Innovation1 Biotech's Total Assets for the quarter that ended in Feb. 2024 was $0.12 Mil.

The historical rank and industry rank for Innovation1 Biotech's Equity-to-Asset or its related term are showing as below:

IVBT's Equity-to-Asset is not ranked *
in the Diversified Financial Services industry.
Industry Median: 0.9
* Ranked among companies with meaningful Equity-to-Asset only.

Innovation1 Biotech  (OTCPK:IVBT) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Innovation1 Biotech Equity-to-Asset Related Terms


Innovation1 Biotech Equity-to-Asset Historical Data

* Premium members only.

The historical data trend for Innovation1 Biotech's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Innovation1 Biotech Equity-to-Asset Chart

Innovation1 Biotech Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only 0.13 -12.81 -1.24 0.07 -45.13

Innovation1 Biotech Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.39 0.33 -45.13 -152.50 -27.35

IVBT vs NVIV, PXMD, SCNI: Equity-to-Asset Comparison

For the Shell Companies subindustry, Innovation1 Biotech's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Innovation1 Biotech Equity-to-Asset vs Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Innovation1 Biotech's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Innovation1 Biotech's Equity-to-Asset falls into.


IVBT
12GF Score
Innovation1 Biotech Inc IVBT
Equity-to-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Innovation1 Biotech Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Innovation1 Biotech's Equity to Asset Ratio for the fiscal year that ended in Aug. 2023 is calculated as

Equity to Asset (A: Aug. 2023 )=Total Stockholders Equity/Total Assets
=-3.43/0.076
=

Innovation1 Biotech's Equity to Asset Ratio for the quarter that ended in Feb. 2024 is calculated as

Equity to Asset (Q: Feb. 2024 )=Total Stockholders Equity/Total Assets
=-3.337/0.122
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Equity-to-Asset →
What does a Equity-to-Asset of -27.35 mean?
Innovation1 Biotech (IVBT) has a Equity-to-Asset of -27.35 as of Feb. 2024. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Innovation1 Biotech and its competitors.
Is Innovation1 Biotech's Equity-to-Asset too high?
Innovation1 Biotech's current Equity-to-Asset is -27.35. Overall, Innovation1 Biotech has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Innovation1 Biotech's Equity-to-Asset compare to NVIV and PXMD?
Innovation1 Biotech's Equity-to-Asset of -27.35 can be compared against companies in the Diversified Financial Services industry. The industry median Equity-to-Asset is 0.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Diversified Financial Services company?
The median Equity-to-Asset among Diversified Financial Services companies is 0.90, based on 544 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Innovation1 Biotech and its competitors. For the Diversified Financial Services industry, the median Equity-to-Asset is 0.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Innovation1 Biotech's current Equity-to-Asset is -27.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innovation1 Biotech stock overvalued right now?
Innovation1 Biotech (IVBT) has a current Equity-to-Asset of -27.35. The current Equity-to-Asset is -27.35. Innovation1 Biotech's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Innovation1 Biotech (IVBT), the current Equity-to-Asset is -27.35 as of Feb. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Innovation1 Biotech Business Description

Address 7 Grand View Avenue, Somerville, MA, USA, 02143
Innovation1 Biotech Inc is a shell company.
12GF Score

Get the complete analysis for IVBT

Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price